0.9945
전일 마감가:
$0.9945
열려 있는:
$0.98
하루 거래량:
73,075
Relative Volume:
0.36
시가총액:
$59.33M
수익:
$8.38M
순이익/손실:
$-27.19M
주가수익비율:
-0.9124
EPS:
-1.09
순현금흐름:
$-13.59M
1주 성능:
-2.50%
1개월 성능:
+14.97%
6개월 성능:
-10.41%
1년 성능:
+0.00%
Opus Genetics Inc Stock (IRD) Company Profile
명칭
Opus Genetics Inc
전화
248-681-9815
주소
8 DAVIS DRIVE, DURHAM
IRD을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
IRD
Opus Genetics Inc
|
0.9945 | 60.85M | 8.38M | -27.19M | -13.59M | -1.09 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-11 | 개시 | Craig Hallum | Buy |
2024-11-13 | 재개 | H.C. Wainwright | Buy |
Opus Genetics Inc 주식(IRD)의 최신 뉴스
Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results - simplywall.st
Opus Genetics, Inc. (NASDAQ:IRD) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates - MSN
Opus Genetics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Opus Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update - GlobeNewswire
IRD Reports Strong Q1 Revenue Growth and Encouraging Trial Data - GuruFocus
Opus Genetics Inc (IRD) Q1 2025 Earnings: EPS of $(0.24) Beats E - GuruFocus
IRD Reports Strong Q1 Revenue Growth and Encouraging Trial Data | IRD Stock News - GuruFocus
Opus Genetics Q1 2025 Financial Results and Corporate Update - TradingView
Opus Gene Therapy Shows 12-Month Vision Restoration Success, Gains FDA RMAT Status | IRD Stock News - Stock Titan
Opus Genetics (IRD) Showcases Advances in Gene Therapy at May Co - GuruFocus
Opus Genetics (IRD) Showcases Advances in Gene Therapy at May Conferences | IRD Stock News - GuruFocus
Opus Genetics to Present Advances in Gene Therapy for Inherited Retinal Diseases at Major Scientific Conferences in May 2025 - Nasdaq
Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May - GlobeNewswire
FDA grants RMAT status to Opus Genetics’ OPGx-LCA5 gene therapy - Yahoo Finance
Opus Genetics (IRD) Secures RMAT Status for Gene Therapy OPGx-LC - GuruFocus
Opus Genetics (IRD) Secures RMAT Status for Gene Therapy OPGx-LCA5 | IRD Stock News - GuruFocus
FDA grants Opus Genetics RMAT status for eye therapy - Investing.com
Opus Genetics Granted FDA Regenerative Medicine Advanced - GlobeNewswire
Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate - The Manila Times
FDA grants Opus Genetics RMAT status for eye therapy By Investing.com - Investing.com South Africa
FDA Fast-Tracks Revolutionary Gene Therapy for Ultra-Rare Inherited Blindness Treatment - Stock Titan
Opus Genetics (IRD) Reveals Promising Gene Therapy Trial Results | IRD Stock News - GuruFocus
Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision - The Manila Times
Opus Genetics Announces Presentation of OPGX-LCA5 Gene - GlobeNewswire
Gene Therapy Breakthrough: Opus Reports 3.5-Line Vision Improvement After 1 Year in Rare Eye Disease Trial - Stock Titan
Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline - Yahoo Finance
Opus Genetics shareholders approve key proposals By Investing.com - Investing.com Nigeria
Opus Genetics shareholders approve key proposals - Investing.com
Ocuphire Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 - marketscreener.com
PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath - markets.businessinsider.com
Opus Genetics (NASDAQ:IRD) Research Coverage Started at Craig Hallum - Defense World
Opus Genetics (IRD) Receives Buy Rating with Promising Gene Ther - GuruFocus
Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns - The Manila Times
Drug company founder pulls plug on proxy fight at her former company - Crain's Detroit Business
Craig-Hallum Initiates Coverage of Opus Genetics (IRD) with Buy Recommendation - Nasdaq
Mina Sooch Issues Open Letter To Opus Genetics' Stockholders - marketscreener.com
Night Vision Disturbances Market to Reach New Heights in Growth - openPR.com
Night Vision Disturbances Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ocuphire Pharma, Viatris - The Globe and Mail
Opus Genetics Inc (IRD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):